SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-22-071445
Filing Date
2022-06-15
Accepted
2022-06-15 16:10:56
Documents
8
Period of Report
2022-07-28

Document Format Files

Seq Description Document Type Size
1 DEF 14A tm2218378-1_def14a.htm DEF 14A 1490733
2 GRAPHIC lg_eaglepharmaceuticals-4c.jpg GRAPHIC 22360
3 GRAPHIC sg_scotttarriff-bw.jpg GRAPHIC 7330
4 GRAPHIC tm2218378d1-bc_index4c.jpg GRAPHIC 131842
5 GRAPHIC tm2218378d1-pc_ceo4c.jpg GRAPHIC 130178
6 GRAPHIC tm2218378d1-pc_director4c.jpg GRAPHIC 368529
7 GRAPHIC tm2218378d1-px_pg1eaglebw.jpg GRAPHIC 907142
8 GRAPHIC tm2218378d1-px_pg2eaglebw.jpg GRAPHIC 823611
  Complete submission text file 0001104659-22-071445.txt   4780422
Mailing Address 50 TICE BOULEVARD, SUITE 315 WOODCLIFF LAKE NJ 07677
Business Address 50 TICE BOULEVARD, SUITE 315 WOODCLIFF LAKE NJ 07677 201-326-5300
EAGLE PHARMACEUTICALS, INC. (Filer) CIK: 0000827871 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36306 | Film No.: 221017882
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences